Adenosine Therapeutics LLC, of Charlottesville, Va., appointed to its board of directors George Beller, president of the American College of Cardiology and a co-founder of Adenosine Therapeutics, and H. Jeff Leighton, president and CEO of BioDesign.

Amylin Pharmaceuticals Inc., of San Diego, named Julia Brown executive vice president, and promoted Daniel Bradbury to executive vice president.

AnorMED Inc., of Vancouver, British Columbia, named Gary Bridger vice president, research and chief scientific officer; Christen Giandomenico vice president, chemical development; and Tammy Mullarky vice president, business development.

AstraZeneca LP, of Wilmington, Del., named John Goddard U.S. chief financial officer.

Atairgin Technologies Inc., of Irvine, Calif., named to its board of directors Susan Foley, a partner in the investment firm of Harris Bretall Sullivan & Smith Inc., of San Francisco.

Athersys Inc., of Cleveland, added to its board of directors C. Thomas Caskey, chief operating officer and president of Cogen Biotech Ventures LP.

Aurora Biosciences Corp., of San Diego, appointed Christopher Krueger vice president, strategic alliances, and Douglas Farrell senior director, investor relations and corporate communications.

Biora AB, of Malmo, Sweden, named Rickard Soderberg president and CEO.

Calydon Inc., of Sunnyvale, Calif., hired David Karpf as vice president, clinical and regulatory affairs.

Calypte Biomedical Corp., of Alameda, Calif., named David Collins chairman of the board. Nancy Katz will become CEO while retaining her title as president and chief financial officer. William Boeger will relinquish his title as chairman of the board, but will continue to serve on the board.

Celera Genomics, of Rockville, Md., named Gerald Steiner senior vice president and general manager, genomics services.

Cellegy Pharmaceuticals Inc., of South San Francisco, appointed Michael Forrest to chairman of the board. Forrest also is the president and CEO. Also appointed to the board was Felix Baker, who manages healthcare investments for the Tisch Family.

No Comments